Biologics

Biologics Market Outlook

The global biologics market is anticipated to reach approximately USD 600 billion by 2035, growing at a robust CAGR of around 8% during the forecast period from 2025 to 2035. This growth is largely driven by the increasing prevalence of chronic diseases, advancements in biotechnology, and heightened investments in biologics research and development. Moreover, the rising demand for personalized medicine and targeted therapies is further propelling the expansion of the market. A notable surge in the aging population globally is also expected to amplify the demand for biologics, particularly in therapeutic areas such as oncology and autoimmune diseases. With the continuous evolution in manufacturing technologies and processes, the biologics market holds significant potential for innovation and growth in the coming years.

Growth Factor of the Market

One of the primary growth factors for the biologics market is the increasing prevalence of chronic and infectious diseases that necessitate the development of more effective treatment options. The shift from traditional small-molecule drugs to biologics, which are often more effective and targeted, is radically altering the treatment landscape. Furthermore, advancements in research fields such as genomics and proteomics are enabling the development of new biologic therapies that are tailored to individual patients, enhancing efficacy and safety. Government initiatives and funding aimed at boosting biopharmaceutical innovations are also contributing significantly to market growth. In addition, the rise in healthcare expenditure across various regions, particularly in developing countries, is creating a larger consumer base for biologics and fostering a favorable environment for future growth.

Key Highlights of the Market

• The biologics market is expected to grow at a CAGR of 8% from 2025 to 2035.
• Monoclonal antibodies dominate the product type segment due to their effectiveness in treating chronic diseases.
• Oncology is the leading application segment, driven by the rising incidence of cancer globally.
• North America holds the largest market share due to advanced healthcare infrastructure and high R&D investments.
• Online pharmacies are witnessing significant growth as consumers increasingly prefer the convenience of online shopping for medications.

By Product Type

Monoclonal Antibodies:

Monoclonal antibodies are among the most significant types of biologics, comprised of identical immune cells that are clones of a unique parent cell. They are designed to target specific antigens, making them highly effective for treating a variety of conditions, especially cancers and autoimmune diseases. Their ability to selectively bind to target cells leads to improved efficacy and reduced side effects compared to traditional therapies. The innovative nature of monoclonal antibodies has led to a surge in their approval and use in clinical settings, contributing significantly to the overall growth of the biologics market. Major companies are heavily investing in R&D to create next-generation monoclonal antibodies that can address unmet medical needs, further enhancing their market presence.

Vaccines:

Vaccines have played a pivotal role in preventing infectious diseases and represent a substantial segment of the biologics market. The recent global focus on vaccination due to the COVID-19 pandemic has accelerated research and development in this area, leading to rapid innovations and approval processes. Vaccines work by stimulating the immune system to recognize and combat pathogens, therefore safeguarding public health. The demand for vaccines is expected to grow exponentially, not just for infectious diseases like influenza and hepatitis, but also for emerging diseases, indicating a robust future for vaccine development and commercialization. The increased awareness about preventive healthcare measures further fuels growth in this segment.

Recombinant Proteins:

Recombinant proteins are a vital category within the biologics sector, produced using recombinant DNA technology. They have found extensive applications in therapeutics, diagnostics, and research. These proteins mimic naturally occurring proteins and are critical for treating diseases such as diabetes, hemophilia, and various hormonal disorders. The ability to produce these proteins in significant quantities and with high purity has led to their widespread use in clinical settings. As biopharmaceutical companies continue to innovate and enhance the production processes for recombinant proteins, the segment is poised for substantial growth, particularly with increasing demand for therapeutic solutions that offer better patient outcomes.

Gene Therapy:

Gene therapy represents a transformative approach within the biologics market, focusing on modifying or manipulating genes to treat or prevent diseases. This innovative technique holds the promise to address congenital genetic disorders and complex diseases that have limited treatment options. The rapid advancements in gene editing technologies, such as CRISPR-Cas9, have propelled the development of gene therapies and increased investment in this area. The potential for long-term therapeutic effects and curative treatments drives significant interest from both pharmaceutical companies and investors. As regulatory landscapes evolve to accommodate these novel therapies, the gene therapy segment is expected to experience remarkable growth in the coming years.

Cellular Therapy:

Cellular therapy, which involves the administration of living cells to treat disease, is gaining traction as a promising therapeutic realm within the biologics market. This segment includes various modalities such as stem cell therapy, CAR-T cell therapy, and regenerative medicine. Cellular therapies offer unique advantages, including the potential to regenerate damaged tissues and modulate immune responses. The increasing incidence of cancer, coupled with advancements in cellular technologies, has stimulated significant research and commercialization of cellular therapies. With ongoing clinical trials and approvals of new cellular products, this segment is set to emerge as a leading contributor to the future landscape of the biologics market.

By Application

Oncology:

The oncology application segment remains the largest in the biologics market, primarily fueled by the increasing rates of cancer diagnoses globally. Biologics, particularly monoclonal antibodies and immune checkpoint inhibitors, play a critical role in the treatment of different cancer types by enhancing the body’s immune response against tumors. The extensive research dedicated to developing targeted cancer therapies that minimize side effects has led to a surge in new product approvals, thereby driving growth in this segment. As the understanding of cancer biology deepens, the demand for novel biologic interventions is expected to continue its upward trajectory, making oncology a focal point for biopharmaceutical innovation.

Autoimmune Diseases:

The treatment of autoimmune diseases is another significant application area for biologics. Conditions such as rheumatoid arthritis, lupus, and multiple sclerosis often require long-term treatment strategies that biologics can effectively address. Monoclonal antibodies and other biologic agents have been proven to help manage symptoms and induce remission in many autoimmune conditions. As awareness and diagnosis of autoimmune diseases increase, along with an aging population that is more susceptible to these disorders, the demand for biologic treatments continues to rise. Ongoing research into the underlying mechanisms of autoimmune diseases is likely to lead to further advancements in biologic therapies, thus propelling market growth.

Infectious Diseases:

Infectious diseases represent a critical application segment, especially in light of the ongoing global health challenges posed by emerging and re-emerging pathogens. Biologics, particularly vaccines and monoclonal antibodies, have been integral in combating infectious diseases by enhancing immune response and providing therapeutic options. The COVID-19 pandemic has underscored the necessity of effective biologics in managing infectious threats, resulting in accelerated vaccine development and approval. As populations become more aware of infectious disease risks, the demand for biologic interventions is anticipated to rise, further solidifying the importance of this application segment in the biologics market.

Cardiovascular Diseases:

Cardiovascular diseases (CVDs) continue to be a leading cause of mortality worldwide, creating a substantial market for biologics aimed at prevention and treatment. Biologics, such as PCSK9 inhibitors and other monoclonal antibodies, have emerged as important therapeutic options in managing cholesterol levels and associated cardiac risks. The shift towards personalized medicine in cardiology, including the use of biologics to target specific patient populations, has become increasingly prominent. Additionally, the growing awareness of lifestyle-related cardiovascular issues is driving demand for innovative biologic solutions. As research evolves and new biologic therapies are developed, the cardiovascular application segment is expected to see significant growth in the coming years.

Neurological Disorders:

Neurological disorders, such as Alzheimer’s disease, multiple sclerosis, and Parkinson’s disease, present unique challenges for treatment, making biologics an increasingly vital area of focus. The complexity of these diseases necessitates innovative therapeutic strategies, and biologics offer the potential for novel interventions targeting underlying pathophysiological mechanisms. Monoclonal antibodies and gene therapies are being explored for their ability to cross the blood-brain barrier and provide targeted treatment. As research in neurobiology advances, coupled with increasing investment in neurological biologics, this application segment is projected to expand significantly, addressing the unmet medical needs of patients with debilitating neurological conditions.

By Distribution Channel

Hospitals:

The hospital distribution channel is a dominant segment in the biologics market, primarily because of the high volume of biologic therapies administered in clinical settings. Hospitals are equipped with specialized staff and facilities to manage complex treatment regimens associated with biologics, particularly in oncology and critical care. The integration of biologic therapies into standard treatment protocols and the availability of specialized pharmacy services enhance the efficiency of biologic administration. As hospitals continue to adopt advanced biologic therapies, this distribution channel is expected to maintain its prominence, contributing significantly to the overall growth of the biologics market.

Specialty Clinics:

Specialty clinics have emerged as a vital distribution channel for biologics, particularly for chronic disease management and specialized therapies. These clinics focus on specific therapeutic areas, such as immunology or oncology, and are often staffed by healthcare professionals with expertise in biologic treatments. The tailored approach offered by specialty clinics allows for a more personalized treatment experience and close monitoring of patient responses to biologics. As patients seek specialized care and the demand for targeted therapies increases, specialty clinics are likely to expand their role in the distribution of biologics, enhancing market dynamics.

Retail Pharmacies:

Retail pharmacies are becoming an increasingly important distribution channel for biologics, especially as more biologic therapies receive approval for outpatient use. The convenience of obtaining medications from retail pharmacies appeals to patients, driving sales and accessibility. Additionally, retail pharmacies often provide patient education and support services, helping patients navigate complex treatment regimens associated with biologics. As pharmacists become more involved in managing biologic therapies, the retail pharmacy segment is expected to grow, making biologics more accessible to a broader patient population.

Online Pharmacies:

Online pharmacies have gained significant traction as a distribution channel for biologics, particularly due to the growing trend of e-commerce and the demand for convenience. Patients appreciate the ability to order medications from the comfort of their homes, and online pharmacies often offer competitive pricing and fast delivery. Moreover, the COVID-19 pandemic has accelerated the shift towards online healthcare services, including the procurement of biologics. As regulations surrounding online medication sales continue to evolve, the contribution of online pharmacies to the overall biologics market is expected to expand, providing enhanced accessibility and convenience for patients.

By Ingredient Type

Blood Factors:

Blood factors, including clotting factors and immunoglobulins, are critical components of biologics used for treating various blood disorders. Patients with hemophilia and other bleeding disorders rely heavily on these biologic therapies for effective management of their conditions. The advancements in recombinant technology have significantly improved the availability and purity of blood factors, leading to enhanced treatment outcomes. The increasing incidence of blood-related disorders and the demand for effective treatment options are driving growth in this ingredient type, making blood factors an essential segment of the biologics market.

Interferons:

Interferons are vital proteins used in the treatment of several diseases, including multiple sclerosis and certain types of cancer and viral infections. As part of the immune response, interferons have demonstrated the ability to inhibit viral replication and modulate the immune system, making them essential in therapeutic applications. The continuous research into the expanding therapeutic potential of interferons is anticipated to drive innovation and growth within this ingredient type. With the increasing focus on immune modulation therapies, the demand for interferons in the biologics market is expected to rise, catering to a variety of health conditions.

Growth Factors:

Growth factors, which are naturally occurring proteins that stimulate cell growth and differentiation, play an essential role in tissue repair and regeneration. Biologics utilizing growth factors are often employed in wound healing, orthopedic therapies, and regenerative medicine. The growing understanding of the mechanisms behind tissue regeneration and repair has led to an increased application of growth factors in clinical settings. As research continues to uncover the potential benefits of growth factors in diverse therapeutic areas, their significance in the biologics market is projected to expand, providing innovative treatment options for patients.

Enzymes:

Enzymes are critical components of biologics that facilitate biochemical reactions within the body, and their therapeutic applications are gaining traction. Enzyme replacement therapies are particularly beneficial for individuals with metabolic disorders, wherein the body lacks specific enzymes necessary for normal function. The increasing prevalence of metabolic diseases and genetic disorders is driving the demand for enzyme-based biologics, contributing to growth in this ingredient type. As advancements in enzyme engineering and production continue, the market for enzymes in biologics is expected to experience significant expansion.

Hormones:

Hormones are biologically active substances that regulate various physiological processes in the body, and they are a crucial segment of the biologics market. Hormonal therapies, such as insulin for diabetes management and growth hormones for growth disorders, represent a significant portion of biologics used in clinical practice. The increasing prevalence of hormonal imbalances and related diseases is driving demand for hormone-based biologics, making this ingredient type an essential aspect of the market. As research progresses and novel hormone therapies emerge, the growth of this segment is expected to continue, providing better treatment options for patients.

By Region

The North American region leads the biologics market, accounting for a substantial share due to its robust healthcare infrastructure, high per capita healthcare expenditure, and advanced biopharmaceutical research and development capabilities. The strong presence of major pharmaceutical companies and a favorable regulatory environment further bolster the growth of the biologics market in this region. North America is projected to witness a CAGR of approximately 7.5% over the forecast period, driven by ongoing innovations in biologics and an increasing focus on personalized medicine. The high adoption rates of biologic therapies in treating chronic diseases, particularly in oncology and autoimmune disorders, significantly contribute to this region's market dominance.

In Europe, the biologics market is also experiencing significant growth, fueled by the rising prevalence of chronic diseases and increasing investments in biotechnology. The region benefits from a well-established healthcare system and a growing patient population requiring advanced treatment options. Countries such as Germany, France, and the UK are at the forefront of biologics research and development, contributing to the overall expansion of the market. The European biologics market is projected to grow at a CAGR of around 6.8% during the forecast period, with an emphasis on expanding the availability of innovative biologic therapies to meet the rising demand from healthcare professionals and patients alike.

Opportunities

The biologics market presents numerous opportunities for growth, particularly in the realm of personalized medicine and targeted therapies. As advancements in genomics and biotechnology continue, the potential to develop biologic treatments tailored to individual patients is becoming increasingly feasible. This approach not only enhances the efficacy of treatments but also minimizes adverse effects, which is a significant concern in traditional therapies. Additionally, the growing emphasis on preventive healthcare is driving demand for vaccines and biologics that can mitigate disease risks, thereby expanding the treatment landscape. Companies focusing on innovative biologic formulations and delivery mechanisms are well-positioned to capture market share and meet the evolving needs of healthcare providers and patients.

Moreover, the expansion of healthcare access in developing regions presents a significant opportunity for the biologics market. As economic growth and healthcare infrastructure improve, the demand for biologics is expected to rise in these regions, driven by the increasing prevalence of chronic diseases and the need for effective treatment options. Collaborations between pharmaceutical companies and local healthcare providers can facilitate the introduction of biologic therapies to underserved markets. The focus on establishing affordable pricing models and ensuring accessibility to biologics will be critical in tapping into these emerging markets, ultimately driving further growth in the global biologics landscape.

Threats

Despite the promising growth trajectory of the biologics market, several threats could impede progress. One of the most significant challenges is the high cost associated with the development and manufacturing of biologics, which can limit access to these therapies for many patients, particularly in lower-income regions. The complexity of biologic products often translates into lengthy and expensive clinical trials, increasing the risk of investment for companies involved in their development. Additionally, potential regulatory hurdles and stringent approval processes can slow down the time to market for new biologic therapies, further exacerbating financial challenges. This environment may deter smaller biopharmaceutical firms from entering the biologics space, consolidating the market into the hands of a few larger players.

Furthermore, the emergence of biosimilars poses a competitive threat to established biologic products. As patents for many original biologics expire, the introduction of biosimilars—products that are highly similar to the original biologic—can lead to price competition and market share erosion for brand-name products. While biosimilars can enhance access to biologic therapies, they also challenge the revenue streams of existing biologic manufacturers. The need for ongoing innovation and differentiation will be crucial for companies to maintain their competitive edge in a landscape increasingly populated with biosimilars, which could ultimately impact long-term profitability in the biologics market.

Competitor Outlook

• Amgen Inc.
• AbbVie Inc.
• Roche Holding AG
• Johnson & Johnson
• Novartis AG
• Pfizer Inc.
• Merck & Co., Inc.
• Bristol-Myers Squibb Company
• Sandoz (a division of Novartis AG)
• Gilead Sciences, Inc.
• Regeneron Pharmaceuticals, Inc.
• Biogen Inc.
• Sanofi S.A.
• Celgene Corporation
• Takeda Pharmaceutical Company Limited

The competitive landscape of the biologics market is characterized by a diverse range of established pharmaceutical and biotechnology companies, all striving to innovate and capture market share. Major players continually invest in research and development to advance their biologic portfolios, with a focus on creating next-generation therapies that address unmet medical needs. Furthermore, partnerships and collaborations among industry players, research institutions, and healthcare providers are becoming increasingly common as companies seek to enhance their technological capabilities and accelerate the development of new biologics. The competitive nature of this market necessitates ongoing innovation, strategic alliances, and an emphasis on patient-centered solutions to achieve sustained growth.

Amgen Inc. stands out in the biologics market as a pioneer of innovative therapies, particularly in oncology and inflammation. Known for its robust pipeline and strong market presence, Amgen has successfully launched several blockbuster biologics, including Enbrel and Neulasta. The company's commitment to advancing biotechnology is evident through its investments in research and partnerships aimed at developing novel treatment options. Additionally, Amgen is actively involved in the biosimilars market, further solidifying its competitive position. The company's focus on improving patient outcomes and expanding access to its therapies has positioned it as a leader in the biologics landscape.

Another key player, AbbVie Inc., has made significant strides in the biologics market, particularly with its flagship product, Humira, which has transformed the treatment of autoimmune diseases. AbbVie's strategy revolves around innovation and expanding its biologic portfolio, with ongoing research efforts aimed at developing new therapies that address various health conditions. The company has also embraced the biosimilars arena to enhance patient access while navigating the complexities of a competitive market. AbbVie's commitment to improving patient care, coupled with its strong R&D capabilities, underpins its position as a formidable contender in the biologics sector.

• 1 Appendix

  • 1.1 List of Tables
  • 1.2 List of Figures

• 2 Introduction

  • 2.1 Market Definition
  • 2.2 Scope of the Report
  • 2.3 Study Assumptions
  • 2.4 Base Currency & Forecast Periods

• 3 Market Dynamics

  • 3.1 Market Growth Factors
  • 3.2 Economic & Global Events
  • 3.3 Innovation Trends
  • 3.4 Supply Chain Analysis

• 4 Consumer Behavior

  • 4.1 Market Trends
  • 4.2 Pricing Analysis
  • 4.3 Buyer Insights

• 5 Key Player Profiles

  • 5.1 Amgen Inc.
    • 5.1.1 Business Overview
    • 5.1.2 Products & Services
    • 5.1.3 Financials
    • 5.1.4 Recent Developments
    • 5.1.5 SWOT Analysis
  • 5.2 AbbVie Inc.
    • 5.2.1 Business Overview
    • 5.2.2 Products & Services
    • 5.2.3 Financials
    • 5.2.4 Recent Developments
    • 5.2.5 SWOT Analysis
  • 5.3 Biogen Inc.
    • 5.3.1 Business Overview
    • 5.3.2 Products & Services
    • 5.3.3 Financials
    • 5.3.4 Recent Developments
    • 5.3.5 SWOT Analysis
  • 5.4 Novartis AG
    • 5.4.1 Business Overview
    • 5.4.2 Products & Services
    • 5.4.3 Financials
    • 5.4.4 Recent Developments
    • 5.4.5 SWOT Analysis
  • 5.5 Pfizer Inc.
    • 5.5.1 Business Overview
    • 5.5.2 Products & Services
    • 5.5.3 Financials
    • 5.5.4 Recent Developments
    • 5.5.5 SWOT Analysis
  • 5.6 Sanofi S.A.
    • 5.6.1 Business Overview
    • 5.6.2 Products & Services
    • 5.6.3 Financials
    • 5.6.4 Recent Developments
    • 5.6.5 SWOT Analysis
  • 5.7 Roche Holding AG
    • 5.7.1 Business Overview
    • 5.7.2 Products & Services
    • 5.7.3 Financials
    • 5.7.4 Recent Developments
    • 5.7.5 SWOT Analysis
  • 5.8 Johnson & Johnson
    • 5.8.1 Business Overview
    • 5.8.2 Products & Services
    • 5.8.3 Financials
    • 5.8.4 Recent Developments
    • 5.8.5 SWOT Analysis
  • 5.9 Merck & Co., Inc.
    • 5.9.1 Business Overview
    • 5.9.2 Products & Services
    • 5.9.3 Financials
    • 5.9.4 Recent Developments
    • 5.9.5 SWOT Analysis
  • 5.10 Celgene Corporation
    • 5.10.1 Business Overview
    • 5.10.2 Products & Services
    • 5.10.3 Financials
    • 5.10.4 Recent Developments
    • 5.10.5 SWOT Analysis
  • 5.11 Gilead Sciences, Inc.
    • 5.11.1 Business Overview
    • 5.11.2 Products & Services
    • 5.11.3 Financials
    • 5.11.4 Recent Developments
    • 5.11.5 SWOT Analysis
  • 5.12 Bristol-Myers Squibb Company
    • 5.12.1 Business Overview
    • 5.12.2 Products & Services
    • 5.12.3 Financials
    • 5.12.4 Recent Developments
    • 5.12.5 SWOT Analysis
  • 5.13 Regeneron Pharmaceuticals, Inc.
    • 5.13.1 Business Overview
    • 5.13.2 Products & Services
    • 5.13.3 Financials
    • 5.13.4 Recent Developments
    • 5.13.5 SWOT Analysis
  • 5.14 Sandoz (a division of Novartis AG)
    • 5.14.1 Business Overview
    • 5.14.2 Products & Services
    • 5.14.3 Financials
    • 5.14.4 Recent Developments
    • 5.14.5 SWOT Analysis
  • 5.15 Takeda Pharmaceutical Company Limited
    • 5.15.1 Business Overview
    • 5.15.2 Products & Services
    • 5.15.3 Financials
    • 5.15.4 Recent Developments
    • 5.15.5 SWOT Analysis

• 6 Market Segmentation

  • 6.1 Biologics Market, By Application
    • 6.1.1 Oncology
    • 6.1.2 Autoimmune Diseases
    • 6.1.3 Infectious Diseases
    • 6.1.4 Cardiovascular Diseases
    • 6.1.5 Neurological Disorders
  • 6.2 Biologics Market, By Product Type
    • 6.2.1 Monoclonal Antibodies
    • 6.2.2 Vaccines
    • 6.2.3 Recombinant Proteins
    • 6.2.4 Gene Therapy
    • 6.2.5 Cellular Therapy
  • 6.3 Biologics Market, By Ingredient Type
    • 6.3.1 Blood Factors
    • 6.3.2 Interferons
    • 6.3.3 Growth Factors
    • 6.3.4 Enzymes
    • 6.3.5 Hormones
  • 6.4 Biologics Market, By Distribution Channel
    • 6.4.1 Hospitals
    • 6.4.2 Specialty Clinics
    • 6.4.3 Retail Pharmacies
    • 6.4.4 Online Pharmacies

• 7 Competitive Analysis

  • 7.1 Key Player Comparison
  • 7.2 Market Share Analysis
  • 7.3 Investment Trends
  • 7.4 SWOT Analysis

• 8 Research Methodology

  • 8.1 Analysis Design
  • 8.2 Research Phases
  • 8.3 Study Timeline

• 9 Future Market Outlook

  • 9.1 Growth Forecast
  • 9.2 Market Evolution

• 10 Geographical Overview

  • 10.1 Europe - Market Analysis
    • 10.1.1 By Country
      • 10.1.1.1 UK
      • 10.1.1.2 France
      • 10.1.1.3 Germany
      • 10.1.1.4 Spain
      • 10.1.1.5 Italy
  • 10.2 Biologics Market by Region
  • 10.3 Asia Pacific - Market Analysis
    • 10.3.1 By Country
      • 10.3.1.1 India
      • 10.3.1.2 China
      • 10.3.1.3 Japan
      • 10.3.1.4 South Korea
  • 10.4 Latin America - Market Analysis
    • 10.4.1 By Country
      • 10.4.1.1 Brazil
      • 10.4.1.2 Argentina
      • 10.4.1.3 Mexico
  • 10.5 North America - Market Analysis
    • 10.5.1 By Country
      • 10.5.1.1 USA
      • 10.5.1.2 Canada
  • 10.6 Middle East & Africa - Market Analysis
    • 10.6.1 By Country
      • 10.6.1.1 Middle East
      • 10.6.1.2 Africa

• 11 Global Economic Factors

  • 11.1 Inflation Impact
  • 11.2 Trade Policies

• 12 Technology & Innovation

  • 12.1 Emerging Technologies
  • 12.2 AI & Digital Trends
  • 12.3 Patent Research

• 13 Investment & Market Growth

  • 13.1 Funding Trends
  • 13.2 Future Market Projections

• 14 Market Overview & Key Insights

  • 14.1 Executive Summary
  • 14.2 Key Trends
  • 14.3 Market Challenges
  • 14.4 Regulatory Landscape

Segments Analyzed in the Report

The global Biologics market is categorized based on

By Product Type

• Monoclonal Antibodies
• Vaccines
• Recombinant Proteins
• Gene Therapy
• Cellular Therapy

By Application

• Oncology
• Autoimmune Diseases
• Infectious Diseases
• Cardiovascular Diseases
• Neurological Disorders

By Distribution Channel

• Hospitals
• Specialty Clinics
• Retail Pharmacies
• Online Pharmacies

By Ingredient Type

• Blood Factors
• Interferons
• Growth Factors
• Enzymes
• Hormones

By Region

• North America
• Europe
• Asia Pacific
• Latin America
• Middle East & Africa

Key Players

• Amgen Inc.
• AbbVie Inc.
• Roche Holding AG
• Johnson & Johnson
• Novartis AG
• Pfizer Inc.
• Merck & Co., Inc.
• Bristol-Myers Squibb Company
• Sandoz (a division of Novartis AG)
• Gilead Sciences, Inc.
• Regeneron Pharmaceuticals, Inc.
• Biogen Inc.
• Sanofi S.A.
• Celgene Corporation
• Takeda Pharmaceutical Company Limited